Advertisement

Familial Cancer

, Volume 14, Issue 1, pp 167–174 | Cite as

Outcomes of genetic evaluation for hereditary cancer syndromes in unaffected individuals

  • Shanna L. GustafsonEmail author
  • Victoria M. Raymond
  • Monica L. Marvin
  • Tobias Else
  • Erika Koeppe
  • Elena M. Stoffel
  • Jessica N. Everett
Original Article

Abstract

Genetic testing (GT) for inherited cancer predisposition is most informative when initiated in individuals with cancer, thus standard practice recommends GT start in an affected individual. This strategy can be frustrating for unaffected consultands and providers. Retrospective review of cases was performed to compare outcomes of testing the unaffected consultand and recommending that testing start in an affected relative. Records from cancer-free consultands (N = 101), presenting to the University of Michigan Cancer Genetics Clinic between 6/1/2011 and 12/30/2011 were reviewed. All genetics records for these consultands were reviewed through 3/31/2013 for GT recommendations (117 total). The unaffected consultand was offered testing in 14.5 % of cases, testing was completed in 64.7 % of these with one mutation identified. Of consultands tested initially, 70.5 % received cancer-screening recommendations based on family history and test results. Testing was recommended to start in an affected family member in 30.7 % of cases. Fifty percent returned to clinic with information on an affected family member; 83.3 % documented that their family member underwent GT with one mutation identified. Consultands reported the affected family member refused testing in 22.2 % and two of these consultands subsequently pursued GT, identifying one mutation. Fifty percent of cases where testing the family member first was recommended were lost to follow-up with 66.6 % of these never given cancer-screening recommendations. Cancer genetic risk evaluation of healthy consultands should consider the option of pursuing GT in the unaffected consultand and should implement a plan for tailored risk management in the absence of informative genetic evaluation within the family.

Keywords

Genetic counseling Genetic testing Hereditary cancer Risk assessment 

Notes

Acknowledgments

The authors would like to thank all of the patients who consented to participate in longitudinal research with the University of Michigan Cancer Genetics Clinic, especially those included in this assessment (University of Michigan IRB HUM00043440). The authors would also like to express gratitude to Dr. Stephen Gruber for reviewing this paper and contributing to the University of Michigan Cancer Genetics Clinic.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Lindor NM, McMaster ML, Lindor CJ, Greene MH, National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38:1–93. doi: 10.1093/jncimonographs/lgn001 PubMedGoogle Scholar
  2. 2.
    Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K, American Society of Clinical Oncology (2010) American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 28(5):893–901. doi: 10.1200/JCO.2009.27.0660 CrossRefPubMedGoogle Scholar
  3. 3.
    Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN, National Comprehensive Cancer Network (2010) Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw 8(5):562–594Google Scholar
  4. 4.
    American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6):565–612. doi: 10.1089/thy.2008.0403 CrossRefGoogle Scholar
  5. 5.
    Lindor NM, Peterson GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, Lynch P, Burke W, Press N (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systemic review. JAMA 296(12):1507–1517CrossRefPubMedGoogle Scholar
  6. 6.
    Kauff ND, Domcheck SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2- associated breast and gynecologic cancer: a multicenter, prospective study. 26(8):1331–1337. doi: 10.1200/JCO.2007.13.9626
  7. 7.
    Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR (2006) Cost-effectiveness of prevention strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144(6):397–406CrossRefPubMedGoogle Scholar
  8. 8.
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2009) Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11(1):35–41. doi: 10.1097/GIM.0b013e31818fa2ff
  9. 9.
    Kontos EZ, Viswanath K (2011) Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer 11(2):142–150. doi: 10.1038/nrc2999 CrossRefPubMedGoogle Scholar
  10. 10.
    Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM (2012) Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 21(2):151–161. doi: 10.1007/s10897-011-9462-x CrossRefPubMedGoogle Scholar
  11. 11.
    Van Dijk S, Timmermans DR, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W (2006) Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol 24(22):3672–3677CrossRefPubMedGoogle Scholar
  12. 12.
    Dancyger C, Wiseman M, Jacobs C, Smith JA, Wallace M, Michie S (2011) Communicating BRCA1/2 genetic test results within the family: a qualitative analysis. Psychol Health 26(8):1018–1035. doi: 10.1080/08870446.2010.525640 CrossRefPubMedGoogle Scholar
  13. 13.
    Lynch HT, Riley BD, Weissman SM, Coronel SM, Kinarsky Y, Lynch JU, Shaw TG, Rubinstein WS (2004) Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: problems in diagnosis, surveillance, and management. Cancer 100(1):53–64CrossRefPubMedGoogle Scholar
  14. 14.
    Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G (2012) Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol 2012:298745. doi: 10.1155/2012/298745 PubMedCentralPubMedGoogle Scholar
  15. 15.
    O’Neill SM, Peters JA, Vogel VG, Feingold E, Rubinstein WS (2006) Referral to cancer genetic counseling: are there stages of readiness? Am J Med Genet C Semin Med Genet 142C(4):221–231CrossRefPubMedGoogle Scholar
  16. 16.
    Cruger DG, Kruse TA, Gerdes AM (2005) ‘Indirect’ BRCA1/2 testing. A useful approach in hereditary breast and ovarian cancer families without a living relative. Clin Genet 68:228–233CrossRefPubMedGoogle Scholar
  17. 17.
    Heiniger L, Butow PN, Price MA, Charles M (2013) Distress in unaffected individuals who decline, delay or remain ineligible for genetic testing for hereditary diseases: a systematic review. Psychooncology 22(9):1930–1945CrossRefPubMedGoogle Scholar
  18. 18.
    Coates R, Williams M, Melillo S, Gudgeon J (2011) Genetic testing for lynch syndrome in individuals newly diagnosed with colorectal cancer to reduce morbidity and mortality from colorectal cancer in their relatives. PLoS Curr 3:RRN1246. doi: 10.1371/currents.RRN1246
  19. 19.
    Jacobsen PB, Valdimarsdottier HB, Brown KL, Offit K (1997) Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 59(5):459–466CrossRefPubMedGoogle Scholar
  20. 20.
    Loescher LJ (2003) Cancer worry in women with hereditary risk factors for breast cancer. Oncol Nurs Forum 30(5):767–772CrossRefPubMedGoogle Scholar
  21. 21.
    Katapodi MC, Northouse L, Pierce P, Milliron KJ, Liu G, Merajver SD (2011) Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. Oncol Nurs Forum 38(5):572–581. doi: 10.1188/11.ONF.572-281
  22. 22.
    Van Dijk S, Otten W, Timmermans DR, van Asperen CJ, Meijers-Heijboer H, Tibben A, Breuning MH, Kievit J (2005) What’s the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genet Med 7(4):239–245CrossRefPubMedGoogle Scholar
  23. 23.
    Engel C, Rahner N, Schulmann K, Holinski-Feder E, Goecke TO, Schackert HK, Kloor M, Steinke V, Vogelsang H, Moslein G, Gorgens H, Dechants S, von Knebel Doeberitz M, Ruschoff J, Friedrichs N, Buttner R, Loeffler M, Propping P, Schmiegel W, German HNPCC Consortium (2010) Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8(2):174–182. doi: 10.1016/j.cgh.2009.10.03 CrossRefPubMedGoogle Scholar
  24. 24.
    Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GC (2013) Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 119(6):1266–1276. doi: 10.1002/cncr.27864 CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Shanna L. Gustafson
    • 1
    Email author
  • Victoria M. Raymond
    • 1
  • Monica L. Marvin
    • 2
  • Tobias Else
    • 3
  • Erika Koeppe
    • 4
  • Elena M. Stoffel
    • 4
  • Jessica N. Everett
    • 1
  1. 1.Division of Molecular Medicine and Genetics, Department of Internal MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Department of Human GeneticsUniversity of MichiganAnn ArborUSA
  3. 3.Division of Metabolism, Endocrinology and DiabetesUniversity of MichiganAnn ArborUSA
  4. 4.Division of GastroenterologyUniversity of MichiganAnn ArborUSA

Personalised recommendations